GlaxoSmithKline_NNP 163_CD Financial_NNP information_NN under_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP Background_NNP Financial_NNP instruments_NNS :_: Financial_NNP instruments_NNS in_IN the_DT comparative_JJ periods_NNS to_TO be_VB presented_VBN in_IN the_DT Annual_JJ Report_NNP 2005_CD i._FW e._FW 2004_CD The_DT IFRS_NNP project_NN and_CC 2003_CD are_VBP recorded_VBN on_IN the_DT existing_VBG UK_NNP GAAP_NNP basis_NN ,_, rather_RB In_IN June_NNP 2002_CD ,_, the_DT Council_NNP of_IN the_DT European_NNP Union_NNP adopted_VBD a_DT than_IN in_IN accordance_NN with_IN IAS_NNP 32_CD Financial_NNP Instruments_NNPS :_: Regulation_NN requiring_VBG listed_VBN companies_NNS in_IN its_PRP$ Member_NNP States_NNPS to_TO Disclosure_NNP and_CC Presentation_NNP and_CC IAS_NNP 39_CD Financial_NNP Instruments_NNPS :_: prepare_VB their_PRP$ consolidated_JJ financial_JJ statements_NNS in_IN accordance_NN Recognition_NN and_CC Measurement_NNP see_VBP below_IN ._.
with_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP from_IN 2005_CD ._.
The_DT first_JJ GlaxoSmithKline_NNP Annual_JJ Report_NNP prepared_VBN under_IN IFRS_NNP The_NNP IFRS_NNP financial_JJ information_NN has_VBZ been_VBN prepared_VBN on_IN the_DT basis_NN will_MD be_VB that_IN for_IN the_DT year_NN ending_VBG 31st_CD December_NNP 2005_CD ._.
The_DT first_JJ of_IN taking_VBG these_DT exemptions_NNS ._.
financial_JJ results_NNS announcement_NN prepared_VBN in_IN accordance_NN with_IN IFRS_NNP will_MD be_VB that_IN for_IN the_DT first_JJ quarter_NN of_IN 2005_CD ._.
Financial_NNP instruments_NNS GlaxoSmithKline_NNP intends_VBZ to_TO adopt_VB IAS_NNP 39_CD in_IN full_JJ ._.
However_RB ,_, one_CD The_DT Groups_NNS project_NN to_TO convert_VB its_PRP$ financial_JJ reporting_NN from_IN UK_NNP of_IN the_DT exemptions_NNS available_JJ under_IN IFRS_NNP 1_CD relaxes_VBZ the_DT requirement_NN GAAP_NNP to_TO IFRS_NNP has_VBZ now_RB been_VBN completed_VBN ,_, subject_JJ to_TO any_DT changes_NNS for_IN comparative_JJ information_NN presented_VBN in_IN the_DT Annual_JJ Report_NNP 2005_CD in_IN standard_JJ and_CC pronouncements_NNS ._.
A_DT training_NN program_NN has_VBZ to_TO comply_VB with_IN IAS_NNP 32_CD and_CC IAS_NNP 39_CD ._.
GlaxoSmithKline_NNP intends_VBZ to_TO been_VBN rolled_VBN out_RP to_TO all_DT finance_NN staff_NN worldwide_NN and_CC the_DT adjusted_VBN take_VBP advantage_NN of_IN this_DT exemption_NN ,_, and_CC so_RB ,_, in_IN 2003_CD and_CC 2004_CD ,_, historical_JJ data_NNS ,_, which_WDT will_MD provide_VB the_DT comparative_JJ information_NN financial_JJ instruments_NNS will_MD be_VB accounted_VBN for_IN and_CC presented_VBN on_IN a_DT under_IN IFRS_NNP in_IN 2005_CD ,_, has_VBZ been_VBN prepared_VBN ._.
The_DT unaudited_JJ consolidated_JJ results_NNS of_IN GlaxoSmithKline_NNP plc_NN On_IN 1st_CD January_NNP 2005_CD there_EX was_VBD an_DT adjustment_NN to_TO the_DT opening_NN converted_VBD from_IN the_DT current_JJ UK_NNP GAAP_NNP basis_NN onto_IN an_DT IFRS_NNP basis_NN balance_NN sheet_NN to_TO reect_VB the_DT movements_NNS from_IN the_DT UK_NNP GAAP_NNP for_IN 2003_CD and_CC 2004_CD are_VBP presented_VBN on_IN pages_NNS 170_CD to_TO 173_CD ._.
As_IN 2003_CD carrying_VBG values_NNS to_TO the_DT IAS_NNP 32_CD and_CC IAS_NNP 39_CD values_NNS ,_, which_WDT for_IN many_JJ will_MD be_VB the_DT earliest_JJS year_NN for_IN which_WDT full_JJ IFRS_NNS financial_JJ statements_NNS financial_JJ instruments_NNS will_MD be_VB fair_JJ value_NN ._.
will_MD be_VB presented_VBN in_IN the_DT Annual_JJ Report_NNP 2005_CD ,_, the_DT transition_NN date_NN to_TO IFRS_NNP for_IN GlaxoSmithKline_NNP is_VBZ 1st_CD January_NNP 2003_CD ._.
Normally_RB The_DT financial_JJ instruments_NNS concerned_VBN are_VBP :_: accounting_NN changes_NNS of_IN this_DT nature_NN would_MD require_VB full_JJ retrospective_NN Held_VBN at_IN fair_JJ value_NN under_IN IFRS_NNP with_IN movements_NNS recorded_VBN in_IN application_NN ,_, but_CC under_IN the_DT IFRS_NNP transitional_JJ rules_NNS ,_, certain_JJ equity_NN :_: adjustments_NNS only_RB have_VBP to_TO be_VB applied_VBN with_IN effect_NN from_IN the_DT Equity_NNP investments_NNS transition_NN date_NN of_IN 1st_CD January_NNP 2003_CD ._.
Liquid_NN investments_NNS Derivatives_NNS classied_VBD as_IN cash_NN ow_NN hedging_VBG instruments_NNS Basis_NN of_IN preparation_NN of_IN data_NNS The_DT IFRS_NNP financial_JJ information_NN has_VBZ been_VBN prepared_VBN on_IN the_DT basis_NN Held_VBN at_IN fair_JJ value_NN under_IN IFRS_NNP with_IN movements_NNS recorded_VBN in_IN of_IN all_DT IFRS_NNP and_CC Standing_VBG Interpretations_NNP Committee_NNP SIC_NNP and_CC the_DT income_NN statement_NN :_: International_NNP Financial_NNP Reporting_NNP Interpretations_NNPS Committee_NNP IFRIC_NNP Equity_NNP collar_NN linked_VBN to_TO the_DT Groups_NNS investment_NN in_IN Quest_NNP interpretations_NNS issued_VBN by_IN the_DT IASB_NNP effective_JJ for_IN 2005_CD reporting_NN ._.
Put_VB and_CC call_VB options_NNS linked_VBN to_TO the_DT Groups_NNS strategic_JJ GlaxoSmithKline_NNP has_VBZ chosen_VBN to_TO adopt_VB the_DT IASBs_NNS amendments_NNS to_TO alliance_NN with_IN Theravance_NNP Inc._NNP ._.
IAS_NNP 19_CD ,_, Employee_NNP Benets_NNPS ,_, early_RB ._.
This_DT permits_VBZ actuarial_JJ gains_NNS and_CC Other_JJ derivatives_NNS not_RB classied_VBD as_IN hedging_VBG instruments_NNS ,_, losses_NNS ,_, differences_NNS between_IN the_DT expected_VBN and_CC actual_JJ returns_NNS and_CC including_VBG embedded_VBN derivatives_NNS the_DT effect_NN of_IN changes_NNS in_IN actuarial_JJ assumptions_NNS to_TO be_VB recognized_VBN Derivatives_NNS classied_VBD as_IN fair_JJ value_NN hedges_NNS together_RB with_IN in_IN the_DT Statement_NN of_IN recognized_VBN income_NN and_CC expense_NN ._.
the_DT hedged_JJ element_NN of_IN the_DT relevant_JJ asset_NN or_CC liability_NN The_DT financial_JJ information_NN presented_VBN under_IN IFRS_NNP is_VBZ unaudited_JJ ._.
Presentation_NN differences_NNS only_RB :_: Non-equity_JJ minority_NN interests_NNS repaid_VBN during_IN 2004_CD ._.
IFRS_NNS 1_CD exemptions_NNS IFRS_VBP 1_CD ,_, First-Time_NNP Adoption_NNP of_IN International_NNP Financial_NNP Reporting_NNP If_IN the_DT IAS_NNP 39_CD valuation_NN rules_NNS had_VBD been_VBN applied_VBN in_IN 2004_CD there_EX Standards_NNPS ,_, permits_VBZ those_DT companies_NNS adopting_VBG IFRS_NNP for_IN the_DT first_JJ would_MD have_VB been_VBN a_DT charge_NN to_TO profit_NN before_IN tax_NN ,_, the_DT largest_JJS time_NN to_TO take_VB some_DT exemptions_NNS from_IN the_DT full_JJ requirements_NNS of_IN IFRS_NNP elements_NNS of_IN which_WDT arise_VBP from_IN the_DT Quest_NNP collar_NN 42_CD million_CD :_: in_IN the_DT transition_NN period_NN ._.
GlaxoSmithKline_NNP intends_VBZ to_TO take_VB the_DT 2003_CD 42_CD million_CD and_CC the_DT Theravance_NNP put_VBD and_CC call_VB options_NNS following_VBG key_JJ exemptions_NNS :_: 53_CD million_CD :_: 2003_CD nil_NN ._.
Valuations_NNS are_VBP inherently_RB unpredictable_JJ and_CC changes_NNS in_IN the_DT fair_JJ values_NNS of_IN financial_JJ instruments_NNS could_MD Business_NNP combinations_NNS :_: Business_NNP combinations_NNS prior_RB to_TO the_DT have_VBP a_DT material_NN impact_NN on_IN the_DT future_JJ results_NNS and_CC financial_JJ transition_NN date_NN 1st_CD January_NNP 2003_CD have_VBP not_RB been_VBN restated_VBN position_NN of_IN GlaxoSmithKline_NNP ._.
onto_IN an_DT IFRS_NNP basis_NN Employee_NN benets_NNS :_: All_DT cumulative_JJ actuarial_JJ gains_NNS and_CC losses_NNS have_VBP been_VBN recognized_VBN in_IN equity_NN at_IN the_DT transition_NN date_NN Share-based_JJ payments_NNS :_: IFRS_NNS 2_CD ,_, Share-based_JJ Payment_NN ,_, applies_VBZ to_TO equity_NN instruments_NNS ,_, such_JJ as_IN share_NN options_NNS granted_VBN since_IN 7th_JJ November_NNP 2002_CD ,_, but_CC GlaxoSmithKline_NNP has_VBZ elected_VBN to_TO adopt_VB full_JJ retrospective_NN application_NN of_IN the_DT standard_JJ 164_CD GlaxoSmithKline_NNP Financial_NNP information_NN under_IN IFRS_NNP IFRS_NNP accounting_NN policies_NNS Foreign_JJ currency_NN transactions_NNS Foreign_JJ currency_NN transactions_NNS by_IN Group_NNP companies_NNS are_VBP booked_VBN The_DT following_JJ IFRS_NNP accounting_NN policies_NNS are_VBP expected_VBN to_TO be_VB applied_VBN in_IN local_JJ currency_NN at_IN the_DT exchange_NN rate_NN ruling_NN on_IN the_DT date_NN of_IN by_IN GlaxoSmithKline_NNP plc_NN in_IN its_PRP$ consolidated_JJ financial_JJ statements_NNS for_IN f_SYM transaction_NN ._.
Foreign_JJ currency_NN assets_NNS and_CC liabilities_NNS are_VBP retranslated_VBN 2005_CD ._.
into_IN local_JJ currency_NN at_IN rates_NNS of_IN exchange_NN ruling_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
Exchange_NNP differences_NNS are_VBP included_VBN in_IN the_DT income_NN statement_NN ._.
Consolidation_NN The_DT consolidated_JJ Financial_NNP statements_NNS include_VBP :_: Revenue_NN the_DT assets_NNS and_CC liabilities_NNS ,_, and_CC the_DT results_NNS and_CC cash_NN ows_NNS ,_, Revenue_NN is_VBZ recognized_VBN in_IN the_DT income_NN statement_NN when_WRB goods_NNS or_CC of_IN the_DT company_NN and_CC its_PRP$ subsidiaries_NNS ,_, including_VBG ESOP_NNP Trusts_NNPS :_: services_NNS are_VBP supplied_VBN or_CC made_VBN available_JJ to_TO external_JJ customers_NNS the_DT Groups_NNS share_NN of_IN the_DT net_JJ assets_NNS and_CC results_NNS of_IN joint_JJ against_IN orders_NNS received_VBN and_CC when_WRB title_NN and_CC risk_NN of_IN loss_NN passes_VBZ to_TO ventures_NNS and_CC associates_NNS ._.
Turnover_NN represents_VBZ net_JJ invoice_NN value_NN after_IN the_DT deduction_NN of_IN discounts_NNS and_CC allowances_NNS given_VBN and_CC accruals_NNS for_IN The_DT Financial_NNP statements_NNS of_IN undertakings_NNS consolidated_VBN are_VBP made_VBN up_RP estimated_VBN future_JJ rebates_NNS and_CC returns_NNS ._.
The_DT methodology_NN and_CC to_TO 31st_CD December_NNP ._.
assumptions_NNS used_VBD to_TO estimate_VB rebates_NNS and_CC returns_NNS are_VBP monitored_JJ Entities_NNS over_IN which_WDT the_DT Group_NNP has_VBZ the_DT ability_NN to_TO exercise_VB control_NN are_VBP and_CC adjusted_VBN regularly_RB in_IN the_DT light_NN of_IN contractual_JJ and_CC historical_JJ accounted_VBD for_IN as_IN subsidiaries_NNS :_: where_WRB the_DT Group_NNP has_VBZ the_DT ability_NN to_TO information_NN and_CC past_JJ experience_NN ._.
Turnover_NN also_RB includes_VBZ coexercise_NN joint_JJ control_NN ,_, they_PRP are_VBP accounted_VBN for_IN as_IN joint_JJ ventures_NNS ,_, and_CC promotion_NN income_NN where_WRB the_DT Group_NNP records_NNS its_PRP$ share_NN of_IN the_DT where_WRB the_DT Group_NNP has_VBZ the_DT ability_NN to_TO exercise_VB significant_JJ inuence_NN ,_, revenue_NN but_CC no_DT related_JJ cost_NN of_IN sales_NNS ._.
Value_NNP added_VBD tax_NN and_CC other_JJ they_PRP are_VBP accounted_VBN for_IN as_IN associates_NNS ._.
sales_NNS taxes_NNS are_VBP excluded_VBN from_IN revenue_NN ._.
Interests_NNS acquired_VBN in_IN entities_NNS are_VBP consolidated_VBN from_IN the_DT effective_JJ Expenditure_NN date_NN of_IN acquisition_NN and_CC interests_NNS sold_VBN are_VBP consolidated_VBN up_RP to_TO the_DT Expenditure_NN is_VBZ recognized_VBN in_IN respect_NN of_IN goods_NNS and_CC services_NNS received_VBN date_NN of_IN disposal_NN ._.
when_WRB supplied_VBN in_IN accordance_NN with_IN contractual_JJ terms_NNS ._.
Provision_NNP is_VBZ Transactions_NNS and_CC balances_NNS between_IN subsidiaries_NNS are_VBP eliminated_VBN :_: made_VBN when_WRB an_DT obligation_NN exists_VBZ for_IN a_DT future_JJ liability_NN in_IN respect_NN of_IN no_DT profit_NN is_VBZ taken_VBN on_IN sales_NNS between_IN subsidiaries_NNS or_CC on_IN sales_NNS to_TO joint_JJ a_DT past_JJ event_NN and_CC where_WRB the_DT amount_NN of_IN the_DT obligation_NN can_MD be_VB ventures_NNS and_CC associates_NNS until_IN the_DT products_NNS are_VBP sold_VBN to_TO customers_NNS reliably_RB estimated_VBN ._.
Advertising_NN and_CC promotion_NN expenditure_NN is_VBZ outside_IN the_DT Group_NNP ._.
Deferred_JJ tax_NN relief_NN on_IN unrealised_JJ intra-Group_JJ charged_VBN to_TO the_DT income_NN statement_NN as_IN incurred_VBN ._.
Shipment_NN costs_NNS on_IN profit_NN is_VBZ accounted_VBN for_IN only_RB to_TO the_DT extent_NN that_IN it_PRP is_VBZ considered_VBN intercompany_NN transfers_NNS are_VBP charged_VBN to_TO cost_NN of_IN sales_NNS :_: distribution_NN recoverable_JJ ._.
costs_NNS on_IN sales_NNS to_TO customers_NNS are_VBP included_VBN in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenditure_NN ._.
Restructuring_NN costs_NNS are_VBP recognized_VBN in_IN Goodwill_NNP arising_VBG on_IN the_DT acquisition_NN of_IN interests_NNS in_IN subsidiaries_NNS ,_, joint_JJ respect_NN of_IN the_DT direct_JJ expenditures_NNS of_IN a_DT business_NN reorganisation_NN ventures_NNS and_CC associates_NNS ,_, representing_VBG the_DT excess_NN of_IN the_DT purchase_NN where_WRB the_DT plans_NNS are_VBP sufciently_RB detailed_VBN and_CC well_RB advanced_VBD ,_, and_CC consideration_NN over_IN the_DT Groups_NNS share_NN of_IN the_DT fair_JJ values_NNS of_IN the_DT where_WRB appropriate_JJ communication_NN to_TO those_DT affected_VBN has_VBZ been_VBN identiable_JJ assets_NNS ,_, liabilities_NNS and_CC contingent_JJ liabilities_NNS acquired_VBN ,_, undertaken_VBN at_IN the_DT balance_NN sheet_NN date_NN ._.
is_VBZ capitalized_VBN as_IN a_DT separate_JJ item_NN in_IN the_DT case_NN of_IN subsidiaries_NNS and_CC as_IN part_NN of_IN the_DT cost_NN of_IN investment_NN in_IN the_DT case_NN of_IN joint_JJ ventures_NNS and_CC Research_NN and_CC development_NN associates_NNS ._.
Goodwill_NN is_VBZ denominated_VBN in_IN the_DT currency_NN of_IN the_DT Research_NNP and_CC development_NN expenditure_NN is_VBZ charged_VBN to_TO the_DT income_NN operation_NN acquired_VBN ._.
In_IN the_DT case_NN of_IN acquisitions_NNS prior_RB to_TO 1998_CD ,_, statement_NN in_IN the_DT period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
Development_NNP goodwill_NN was_VBD written_VBN off_RP directly_RB to_TO equity_NN :_: on_IN a_DT subsequent_JJ expenditure_NN is_VBZ capitalized_VBN when_WRB the_DT criteria_NNS for_IN recognizing_VBG an_DT asset_NN disposal_NN of_IN assets_NNS from_IN such_JJ acquisitions_NNS ,_, any_DT related_JJ goodwill_NN are_VBP met_VBN ,_, usually_RB at_IN the_DT point_NN of_IN regulatory_JJ ling_NN in_IN a_DT major_JJ market_NN ._.
remains_VBZ in_IN equity_NN and_CC is_VBZ not_RB charged_VBN to_TO the_DT consolidated_JJ income_NN Property_NN ,_, plant_NN and_CC equipment_NN used_VBN for_IN research_NN and_CC development_NN statement_NN ._.
is_VBZ depreciated_VBN in_IN accordance_NN with_IN the_DT Groups_NNS policy_NN ._.
The_DT results_NNS and_CC assets_NNS and_CC liabilities_NNS of_IN associates_NNS and_CC joint_JJ ventures_NNS are_VBP incorporated_VBN into_IN the_DT consolidated_JJ financial_JJ statements_NNS using_VBG Environmental_JJ expenditure_NN the_DT equity_NN method_NN of_IN accounting_NN ._.
Environmental_NNP expenditure_NN related_VBN to_TO existing_VBG conditions_NNS resulting_VBG from_IN past_JJ or_CC current_JJ operations_NNS and_CC from_IN which_WDT no_DT current_JJ or_CC Assets_NNS and_CC liabilities_NNS of_IN overseas_JJ subsidiaries_NNS ,_, associates_NNS and_CC joint_JJ future_NN benefit_NN is_VBZ discernible_JJ is_VBZ charged_VBN to_TO the_DT income_NN statement_NN ._.
ventures_NNS including_VBG related_JJ goodwill_NN ,_, are_VBP translated_VBN into_IN sterling_NN at_IN The_DT Group_NNP recognizes_VBZ its_PRP$ liability_NN on_IN a_DT site-by-site_JJ basis_NN when_WRB it_PRP can_MD rates_NNS of_IN exchange_NN ruling_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT results_NNS and_CC be_VB reliably_RB estimated_VBN ._.
This_DT liability_NN includes_VBZ the_DT Groups_NNS portion_NN of_IN cash_NN ows_NNS of_IN overseas_JJ subsidiaries_NNS ,_, associates_NNS and_CC joint_JJ ventures_NNS the_DT total_JJ costs_NNS and_CC also_RB a_DT portion_NN of_IN other_JJ potentially_RB responsible_JJ are_VBP translated_VBN into_IN sterling_NN using_VBG average_JJ rates_NNS of_IN exchange_NN ._.
parties_NNS costs_NNS when_WRB it_PRP is_VBZ probable_JJ that_IN they_PRP will_MD not_RB be_VB able_JJ to_TO Exchange_NNP adjustments_NNS arising_VBG when_WRB the_DT opening_NN net_JJ assets_NNS and_CC satisfy_VB their_PRP$ respective_JJ shares_NNS of_IN the_DT clean-up_JJ obligation_NN ._.
Recoveries_NNS the_DT profits_NNS for_IN the_DT year_NN retained_VBN by_IN overseas_JJ subsidiaries_NNS ,_, associates_NNS of_IN reimbursements_NNS are_VBP recorded_VBN as_IN assets_NNS when_WRB virtually_RB certain_JJ ._.
and_CC joint_JJ ventures_NNS are_VBP translated_VBN into_IN sterling_NN ,_, less_JJR exchange_NN differences_NNS arising_VBG on_IN related_VBN foreign_JJ currency_NN borrowings_NNS which_WDT hedge_VBP the_DT Groups_NNS net_JJ investment_NN in_IN these_DT operations_NNS ,_, are_VBP taken_VBN to_TO a_DT separate_JJ component_NN of_IN equity_NN ._.
When_WRB translating_VBG into_IN sterling_NN the_DT assets_NNS ,_, liabilities_NNS ,_, results_NNS and_CC cash_NN ows_NNS of_IN overseas_JJ subsidiaries_NNS ,_, associates_NNS and_CC joint_JJ ventures_NNS which_WDT are_VBP reported_VBN in_IN currencies_NNS of_IN hyper-inationary_JJ economies_NNS ,_, adjustments_NNS are_VBP made_VBN to_TO reect_VB current_JJ price_NN levels_NNS ._.
Any_DT loss_NN on_IN net_JJ monetary_JJ assets_NNS is_VBZ charged_VBN to_TO the_DT consolidated_JJ income_NN statement_NN ._.
Financial_NNP information_NN under_IN IFRS_NNP GlaxoSmithKline_NNP 165_CD IFRS_NNP accounting_NN policies_NNS continued_VBD Property_NN ,_, plant_NN and_CC equipment_NN Property_NN ,_, plant_NN and_CC equipment_NN PP&E_NNP is_VBZ stated_VBN at_IN the_DT cost_NN of_IN Pensions_NNS and_CC other_JJ post-employment_NN benets_NNS purchase_NN or_CC construction_NN less_RBR provisions_NNS for_IN depreciation_NN and_CC The_DT costs_NNS of_IN providing_VBG pensions_NNS under_IN dened_VBN benefit_NN schemes_NNS are_VBP impairment_NN ._.
Financing_NN costs_NNS are_VBP not_RB capitalized_VBN ._.
calculated_VBN using_VBG the_DT projected_VBN unit_NN credit_NN method_NN and_CC spread_NN over_IN the_DT period_NN during_IN which_WDT benefit_NN is_VBZ expected_VBN to_TO be_VB derived_VBN from_IN the_DT Depreciation_NN is_VBZ calculated_VBN to_TO write_VB off_RP the_DT cost_NN of_IN PP&E_NNP ,_, excluding_VBG employees_NNS services_NNS ,_, in_IN accordance_NN with_IN the_DT advice_NN of_IN qualied_JJ freehold_JJ land_NN ,_, using_VBG the_DT straight-line_JJ basis_NN over_IN its_PRP$ expected_VBN useful_JJ actuaries_NNS ._.
Pension_NNP obligations_NNS are_VBP measured_VBN as_IN the_DT present_JJ value_NN life_NN ._.
The_DT normal_JJ expected_VBN useful_JJ lives_NNS of_IN the_DT major_JJ categories_NNS of_IN of_IN estimated_JJ future_JJ cash_NN ows_VBZ discounted_VBN at_IN rates_NNS reecting_VBG the_DT PP&E_NNP are_VBP reviewed_VBN annually_RB and_CC are_VBP :_: yields_NNS of_IN high_JJ quality_NN corporate_JJ bonds_NNS ._.
Pension_NNP scheme_NN assets_NNS are_VBP Freehold_NNP buildings_NNS 20_CD to_TO 50_CD years_NNS measured_VBN at_IN fair_JJ value_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
Actuarial_JJ gains_NNS Leasehold_NNP land_NN and_CC Lease_NNP term_NN or_CC 20_CD to_TO 50_CD years_NNS and_CC losses_NNS ,_, differences_NNS between_IN the_DT expected_VBN and_CC actual_JJ returns_NNS ,_, buildings_NNS and_CC the_DT effect_NN of_IN changes_NNS in_IN actuarial_JJ assumptions_NNS are_VBP recognized_VBN Plant_NN and_CC machinery_NN 10_CD to_TO 20_CD years_NNS in_IN the_DT Statement_NN of_IN recognized_VBN income_NN and_CC expense_NN in_IN the_DT Fixtures_NNS and_CC equipment_NN 3_CD to_TO 10_CD years_NNS year_NN they_PRP arise_VBP ._.
The_DT Groups_NNS contributions_NNS to_TO dened_JJ contribution_NN plans_NNS are_VBP On_IN disposal_NN of_IN PP&E_NNP ,_, the_DT cost_NN and_CC related_JJ accumulated_VBN charged_VBN to_TO the_DT income_NN statement_NN as_IN incurred_VBN ._.
depreciation_NN and_CC impairments_NNS are_VBP removed_VBN from_IN the_DT financial_JJ statements_NNS and_CC the_DT net_JJ amount_NN ,_, less_JJR any_DT proceeds_NNS ,_, is_VBZ taken_VBN to_TO The_DT costs_NNS of_IN other_JJ post-employment_NN liabilities_NNS are_VBP calculated_VBN in_IN a_DT the_DT income_NN statement_NN ._.
similar_JJ way_NN to_TO dened_VBN benefit_NN pension_NN schemes_NNS and_CC spread_NN over_IN the_DT period_NN during_IN which_WDT benefit_NN is_VBZ expected_VBN to_TO be_VB derived_VBN from_IN Leases_NNPS the_DT employees_NNS services_NNS ,_, in_IN accordance_NN with_IN the_DT advice_NN of_IN qualied_JJ Leasing_NNP agreements_NNS which_WDT transfer_VBP to_TO the_DT Group_NNP substantially_RB actuaries_NNS ._.
all_DT the_DT benets_NNS and_CC risks_NNS of_IN ownership_NN of_IN an_DT asset_NN are_VBP treated_VBN as_IN finance_NN leases_NNS ,_, as_IN if_IN the_DT asset_NN had_VBD been_VBN purchased_VBN outright_RB ._.
The_DT Legal_NNP and_CC other_JJ disputes_NNS assets_NNS are_VBP included_VBN in_IN PP&E_NNP or_CC computer_NN software_NN and_CC the_DT capital_NN Provision_NNP is_VBZ made_VBN for_IN anticipated_JJ settlement_NN costs_NNS where_WRB a_DT elements_NNS of_IN the_DT leasing_NN commitments_NNS are_VBP shown_VBN as_IN obligations_NNS reasonable_JJ estimate_NN can_MD be_VB made_VBN of_IN the_DT likely_JJ outcome_NN of_IN legal_JJ or_CC under_IN finance_NN leases_NNS ._.
Assets_NNS held_VBN under_IN finance_NN leases_NNS are_VBP other_JJ disputes_NNS against_IN the_DT Group_NNP ._.
In_IN addition_NN provision_NN is_VBZ made_VBN for_IN depreciated_VBN on_IN a_DT basis_NN consistent_JJ with_IN similar_JJ owned_VBN assets_NNS or_CC legal_JJ or_CC other_JJ expenses_NNS arising_VBG from_IN claims_NNS received_VBN or_CC other_JJ the_DT lease_NN term_NN if_IN shorter_JJR ._.
The_DT interest_NN element_NN of_IN the_DT lease_NN rental_JJ disputes_NNS ._.
In_IN respect_NN of_IN product_NN liability_NN claims_NNS related_VBN to_TO products_NNS is_VBZ included_VBN in_IN the_DT income_NN statement_NN ._.
All_DT other_JJ leases_NNS are_VBP operating_VBG where_WRB there_EX is_VBZ sufficient_JJ history_NN of_IN claims_NNS made_VBN and_CC settlements_NNS ,_, an_DT leases_NNS and_CC the_DT annual_JJ rentals_NNS are_VBP included_VBN in_IN the_DT income_NN statement_NN incurred_VBN but_CC not_RB reported_VBD IBNR_NNP actuarial_JJ technique_NN is_VBZ used_VBN to_TO on_IN a_DT straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN ._.
determine_VB a_DT reasonable_JJ estimate_NN of_IN the_DT Groups_NNS exposure_NN to_TO unasserted_JJ claims_NNS for_IN those_DT products_NNS and_CC a_DT provision_NN is_VBZ made_VBN on_IN Goodwill_NNP that_WDT basis_NN ._.
No_DT provision_NN is_VBZ made_VBN for_IN other_JJ unasserted_JJ claims_NNS or_CC Goodwill_NNP is_VBZ stated_VBN at_IN cost_NN less_JJR impairments_NNS ._.
Goodwill_NN is_VBZ deemed_VBN to_TO where_WRB an_DT obligation_NN exists_VBZ under_IN a_DT dispute_NN but_CC it_PRP is_VBZ not_RB possible_JJ to_TO have_VB an_DT indefinite_JJ useful_JJ life_NN and_CC is_VBZ tested_VBN for_IN impairment_NN annually_RB ._.
Costs_NNS associated_VBN with_IN claims_NNS made_VBN by_IN the_DT Group_NNP against_IN third_JJ parties_NNS are_VBP charged_VBN to_TO the_DT income_NN Where_WRB the_DT fair_JJ value_NN of_IN the_DT interest_NN acquired_VBN in_IN an_DT entitys_JJ assets_NNS ,_, statement_NN as_IN they_PRP are_VBP incurred_VBN ._.
liabilities_NNS and_CC contingent_JJ liabilities_NNS exceeds_VBZ the_DT consideration_NN paid_VBN ,_, this_DT excess_NN is_VBZ recognized_VBN immediately_RB as_IN a_DT gain_NN in_IN the_DT income_NN Employee_NN share_NN plans_VBZ statement_NN ._.
Incentives_NNS in_IN the_DT form_NN of_IN shares_NNS are_VBP provided_VBN to_TO employees_NNS under_IN share_NN option_NN and_CC share_NN award_NN schemes_NNS ._.
These_DT options_NNS and_CC awards_NNS are_VBP fair_JJ valued_VBN at_IN their_PRP$ grant_NN dates_NNS and_CC the_DT cost_NN is_VBZ charged_VBN to_TO the_DT income_NN statement_NN over_IN the_DT relevant_JJ vesting_NN periods_NNS ._.
The_DT Group_NNP provides_VBZ finance_NN to_TO ESOP_NNP Trusts_NNPS to_TO purchase_VB company_NN shares_NNS on_IN the_DT open_JJ market_NN to_TO meet_VB the_DT obligation_NN to_TO provide_VB shares_NNS when_WRB employees_NNS exercise_VBP their_PRP$ options_NNS or_CC awards_NNS ._.
Costs_NNS of_IN running_VBG the_DT ESOP_NNP Trusts_NNPS are_VBP charged_VBN to_TO the_DT income_NN statement_NN ._.
Shares_NNS held_VBN by_IN the_DT ESOP_NNP Trusts_NNPS are_VBP deducted_VBN from_IN other_JJ reserves_NNS and_CC held_VBN at_IN the_DT value_NN of_IN the_DT proceeds_NNS receivable_NN from_IN employees_NNS on_IN exercise_NN ._.
If_IN there_EX is_VBZ deemed_VBN to_TO be_VB a_DT permanent_JJ impairment_NN in_IN value_NN this_DT is_VBZ reected_VBN by_IN a_DT transfer_NN to_TO retained_VBN earnings_NNS ._.
166_CD GlaxoSmithKline_NNP Financial_NNP information_NN under_IN IFRS_NNP IFRS_NNP accounting_NN policies_NNS continued_VBD Inventories_NNS Inventories_NNS are_VBP included_VBN in_IN the_DT financial_JJ statements_NNS at_IN the_DT lower_JJR Intangible_NNP xed_VBD assets_NNS of_IN cost_NN including_VBG raw_JJ materials_NNS ,_, direct_JJ labor_NN ,_, other_JJ direct_JJ costs_NNS Intangible_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR provisions_NNS for_IN amortisation_NN and_CC related_JJ production_NN overheads_NNS and_CC net_JJ realisable_JJ value_NN ._.
generally_RB determined_VBN on_IN a_DT first_JJ in_IN ,_, first_RB out_IN basis_NN ._.
Licences_NNP ,_, patents_NNS ,_, know-how_NN and_CC marketing_NN rights_NNS separately_RB acquired_VBN or_CC acquired_VBN as_IN part_NN of_IN a_DT business_NN combination_NN are_VBP Taxation_NNP amortised_VBD over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS from_IN the_DT time_NN they_PRP Deferred_VBD tax_NN is_VBZ provided_VBN in_IN full_JJ ,_, using_VBG the_DT liability_NN method_NN ,_, on_IN are_VBP available_JJ for_IN use_NN ._.
The_DT estimated_VBN useful_JJ lives_NNS for_IN determining_VBG temporary_JJ differences_NNS arising_VBG between_IN the_DT tax_NN bases_NNS of_IN assets_NNS the_DT amortisation_NN charge_NN are_VBP reviewed_VBN annually_RB ,_, and_CC take_VB into_IN and_CC liabilities_NNS and_CC their_PRP$ carrying_VBG amounts_NNS in_IN the_DT financial_JJ account_NN the_DT estimated_VBN time_NN it_PRP takes_VBZ to_TO bring_VB the_DT compounds_NNS or_CC statements_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN products_NNS to_TO market_NN ._.
Any_DT development_NN costs_VBZ incurred_VBN by_IN the_DT Group_NNP that_IN it_PRP is_VBZ probable_JJ that_IN future_JJ taxable_JJ profits_NNS will_MD be_VB available_JJ and_CC associated_VBN with_IN acquired_VBN licences_NNS ,_, patents_NNS ,_, know-how_NN or_CC against_IN which_WDT the_DT temporary_JJ differences_NNS can_MD be_VB utilised_VBN ._.
marketing_NN rights_NNS are_VBP written_VBN off_RP to_TO the_DT income_NN statement_NN Deferred_JJ tax_NN is_VBZ provided_VBN on_IN temporary_JJ differences_NNS arising_VBG on_IN when_WRB incurred_VBN ,_, unless_IN the_DT criteria_NNS for_IN recognition_NN of_IN an_DT internally_RB investments_NNS in_IN subsidiaries_NNS ,_, associates_NNS and_CC joint_JJ ventures_NNS ,_, except_IN generated_VBN intangible_JJ asset_NN are_VBP met_VBN ._.
where_WRB the_DT timing_NN of_IN the_DT reversal_NN of_IN the_DT temporary_JJ difference_NN can_MD Brands_NNS are_VBP valued_VBN independently_RB as_IN part_NN of_IN the_DT fair_JJ value_NN of_IN be_VB controlled_VBN and_CC it_PRP is_VBZ probable_JJ that_IN the_DT temporary_JJ difference_NN businesses_NNS acquired_VBN from_IN third_JJ parties_NNS where_WRB the_DT brand_NN has_VBZ a_DT will_MD not_RB reverse_VB in_IN the_DT foreseeable_JJ future_NN ._.
value_NN which_WDT is_VBZ substantial_JJ and_CC long-term_JJ and_CC where_WRB the_DT brands_NNS Deferred_VBN tax_NN is_VBZ provided_VBN using_VBG rates_NNS of_IN tax_NN that_WDT have_VBP been_VBN enacted_VBN can_MD be_VB sold_VBN separately_RB from_IN the_DT rest_NN of_IN the_DT businesses_NNS acquired_VBN ._.
or_CC substantively_RB enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
Deferred_JJ tax_NN Brands_NNS are_VBP amortised_VBN over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS ,_, except_IN liabilities_NNS and_CC assets_NNS are_VBP not_RB discounted_VBN ._.
where_WRB it_PRP is_VBZ considered_VBN that_IN the_DT useful_JJ economic_JJ life_NN is_VBZ indefinite_JJ ._.
Prior_RB to_TO 1998_CD ,_, acquired_VBN minor_JJ brands_NNS and_CC similar_JJ intangibles_NNS were_VBD Derivative_JJ f_SYM financial_JJ instruments_NNS and_CC hedging_VBG activities_NNS eliminated_VBN in_IN the_DT Group_NNP balance_NN sheet_NN against_IN reserves_NNS in_IN the_DT year_NN Derivative_JJ financial_JJ instruments_NNS are_VBP used_VBN to_TO manage_VB exposure_NN to_TO of_IN acquisition_NN ._.
market_NN risks_NNS from_IN treasury_NN operations_NNS ._.
The_DT principal_JJ derivative_NN instruments_NNS used_VBN by_IN GlaxoSmithKline_NNP are_VBP foreign_JJ currency_NN swaps_NNS ,_, The_DT costs_NNS of_IN acquiring_VBG and_CC developing_VBG computer_NN software_NN for_IN interest_NN rate_NN swaps_NNS and_CC forward_RB foreign_JJ exchange_NN contracts_NNS ._.
internal_JJ use_NN and_CC internet_NN sites_NNS for_IN external_JJ use_NN are_VBP capitalized_VBN as_IN The_DT Group_NNP does_VBZ not_RB hold_VB or_CC issue_VB derivative_JJ financial_JJ instruments_NNS intangible_JJ xed_VBD assets_NNS where_WRB the_DT software_NN or_CC site_NN supports_VBZ a_DT for_IN trading_NN or_CC speculative_JJ purposes_NNS ._.
significant_JJ business_NN system_NN and_CC the_DT expenditure_NN leads_VBZ to_TO the_DT creation_NN of_IN a_DT durable_JJ asset_NN ._.
ERP_NNP systems_NNS software_NN is_VBZ amortised_VBN Derivative_JJ financial_JJ instruments_NNS are_VBP initially_RB recognized_VBN in_IN the_DT over_JJ seven_CD years_NNS and_CC other_JJ computer_NN software_NN over_IN three_CD to_TO balance_VB sheet_NN at_IN cost_NN and_CC then_RB remeasured_VBD at_IN subsequent_JJ five_CD years_NNS ._.
reporting_VBG dates_NNS to_TO fair_JJ value_NN ._.
Hedging_VBG derivatives_NNS are_VBP classied_VBN on_IN inception_NN as_IN fair_JJ value_NN hedges_NNS ,_, cash_NN ow_NN hedges_NNS or_CC net_JJ Impairment_NN of_IN non-current_JJ assets_NNS investment_NN hedges_NNS ._.
The_DT carrying_VBG values_NNS of_IN all_DT non-current_JJ assets_NNS are_VBP reviewed_VBN for_IN Changes_NNS in_IN the_DT fair_JJ value_NN of_IN derivatives_NNS designated_VBN as_IN fair_JJ value_NN impairment_NN when_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT assets_NNS might_MD hedges_NNS are_VBP recorded_VBN in_IN the_DT income_NN statement_NN ,_, with_IN the_DT changes_NNS be_VB impaired_VBN ._.
Additionally_RB ,_, goodwill_NN ,_, intangible_JJ assets_NNS with_IN in_IN the_DT fair_JJ value_NN of_IN the_DT hedged_JJ asset_NN or_CC liability_NN ._.
indefinite_JJ useful_JJ lives_NNS and_CC intangible_JJ assets_NNS which_WDT are_VBP not_RB yet_RB available_JJ for_IN use_NN are_VBP tested_VBN for_IN impairment_NN annually_RB ._.
Any_DT Changes_NNS in_IN the_DT fair_JJ value_NN of_IN derivatives_NNS designated_VBN as_IN cash_NN ow_NN provision_NN for_IN impairment_NN is_VBZ charged_VBN to_TO the_DT income_NN statement_NN hedges_NNS are_VBP recognized_VBN in_IN equity_NN ._.
Amounts_NNS deferred_VBN in_IN equity_NN are_VBP in_IN the_DT year_NN concerned_VBN ._.
transferred_VBN to_TO the_DT income_NN statement_NN in_IN line_NN with_IN the_DT hedged_VBN forecast_NN transaction_NN ._.
Investments_NNP in_IN joint_JJ ventures_NNS and_CC associates_NNS Hedges_NNP of_IN net_JJ investments_NNS in_IN foreign_JJ entities_NNS are_VBP accounted_VBN for_IN Investments_NNP in_IN joint_JJ ventures_NNS and_CC associates_NNS are_VBP carried_VBN in_IN the_DT in_IN a_DT similar_JJ way_NN to_TO cash_VB ow_NN hedges_NNS ._.
consolidated_JJ balance_NN sheet_NN at_IN the_DT Groups_NNS share_NN of_IN their_PRP$ net_JJ assets_NNS at_IN date_NN of_IN acquisition_NN and_CC of_IN their_PRP$ post-acquisition_JJ retained_VBN profits_NNS Changes_NNS in_IN the_DT fair_JJ value_NN of_IN any_DT derivative_JJ instruments_NNS that_WDT do_VBP or_CC losses_NNS together_RB with_IN any_DT goodwill_NN arising_VBG on_IN the_DT acquisition_NN ._.
not_RB qualify_VB for_IN hedge_JJ accounting_NN are_VBP recognized_VBN immediately_RB in_IN the_DT income_NN statement_NN ._.
Available-for-sale_JJ investments_NNS Available-for-sale_JJ investments_NNS are_VBP initially_RB recorded_VBN at_IN cost_NN and_CC Debt_NN instruments_NNS then_RB remeasured_VBD at_IN subsequent_JJ reporting_NN dates_NNS to_TO fair_JJ value_NN ._.
Unhedged_JJ debt_NN instruments_NNS are_VBP stated_VBN at_IN the_DT amount_NN of_IN net_JJ Unrealised_JJ gains_NNS and_CC losses_NNS on_IN available-for-sale_JJ investments_NNS are_VBP proceeds_NNS ,_, adjusted_VBN to_TO amortise_VB the_DT issue_NN costs_NNS of_IN the_DT debt_NN over_IN recognized_VBN directly_RB in_IN equity_NN ._.
On_IN disposal_NN or_CC impairment_NN of_IN the_DT its_PRP$ term_NN ._.
investments_NNS ,_, the_DT gains_NNS and_CC losses_NNS in_IN equity_NN are_VBP recycled_VBN into_IN the_DT income_NN statement_NN ._.
Equity_NNP investments_NNS are_VBP recorded_VBN in_IN non-current_JJ assets_NNS unless_IN they_PRP are_VBP expected_VBN to_TO be_VB sold_VBN within_IN one_CD year_NN ._.
Financial_NNP information_NN under_IN IFRS_NNP GlaxoSmithKline_NNP 167_CD IFRS_NNP adjustments_NNS The_DT adjustment_NN for_IN share-based_JJ payments_NNS is_VBZ expected_VBN to_TO reduce_VB to_TO a_DT more_RBR normal_JJ level_NN of_IN 200-250_CD million_CD by_IN 2005_CD ._.
The_DT A_DT summary_NN of_IN the_DT principal_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC considerably_RB higher_JJR charge_NN in_IN 2004_CD and_CC 2003_CD arises_VBZ from_IN two_CD IFRS_NNS as_IN they_PRP apply_VBP to_TO GlaxoSmithKline_NNP is_VBZ set_VBN out_RP below_IN and_CC the_DT main_JJ factors_NNS ._.
Relatively_RB few_JJ share_NN options_NNS were_VBD granted_VBN during_IN financial_JJ effect_NN is_VBZ shown_VBN on_IN pages_NNS 170_CD to_TO 173_CD ._.
2000_CD when_WRB the_DT GW_NNP SB_NNP merger_NN was_VBD being_VBG nalised_VBN ,_, but_CC then_RB in_IN Customer_NN allowances_NNS 2001_CD there_EX was_VBD a_DT full_JJ catch-up_NN grant_NN early_RB in_IN the_DT year_NN followed_VBD This_DT adjustment_NN is_VBZ a_DT reclassication_NN between_IN turnover_NN and_CC by_IN the_DT normal_JJ annual_JJ grant_NN in_IN November_NNP 2001_CD ._.
In_IN addition_NN ,_, the_DT expenses_NNS with_IN no_DT profit_NN or_CC cash_NN ow_NN effect_NN ._.
IFRS_NNP has_VBZ no_DT detailed_JJ grants_NNS in_IN 2001_CD were_VBD made_VBN at_IN an_DT average_JJ share_NN price_NN in_IN excess_NN of_IN rules_NNS in_IN relation_NN to_TO when_WRB certain_JJ marketing_NN and_CC promotional_JJ 18_CD ._.
These_DT share_NN options_NNS will_MD become_VB exercisable_JJ in_IN 2004_CD and_CC expenditure_NN should_MD be_VB deducted_VBN from_IN turnover_NN rather_RB than_IN therefore_RB fall_VB out_IN of_IN the_DT charge_NN in_IN 2005_CD ,_, when_WRB the_DT charge_NN will_MD recorded_VBN as_IN an_DT expense_NN ._.
However_RB ,_, these_DT rules_NNS do_VBP exist_VB under_IN US_NNP reect_VB more_JJR current_JJ share_NN prices_NNS and_CC more_JJR normal_JJ grant_NN levels_NNS ._.
GAAP_NNP in_IN EITF_NNP 01-09_CD ,_, Accounting_NNP for_IN Consideration_NNP Given_VBN by_IN a_DT Vendor_NNP to_TO a_DT Customer_NN ,_, which_WDT requires_VBZ most_RBS marketing_NN ,_, advertising_NN ,_, Coreg_NNP capitalization_NN and_CC amortisation_NN and_CC promotion_NN payments_NNS made_VBD to_TO customers_NNS to_TO be_VB deducted_VBN from_IN The_DT North_JJ American_JJ rights_NNS to_TO Coreg_NNP were_VBD acquired_VBN at_IN the_DT time_NN of_IN turnover_NN ._.
This_DT has_VBZ the_DT most_RBS significant_JJ impact_NN in_IN the_DT Consumer_NN the_DT GW_NNP SB_NNP merger_NN as_IN partial_JJ consideration_NN for_IN the_DT required_VBN disposal_NN Healthcare_NNP business_NN where_WRB payments_NNS to_TO large_JJ retailers_NNS for_IN in-store_JJ of_IN Kytril_NNP to_TO Roche_NNP ._.
Under_IN UK_NNP GAAP_NNP this_DT was_VBD accounted_VBN for_IN as_IN advertising_NN ,_, preferential_JJ shelf-space_NN ,_, product_NN listings_NNS etc._FW ._.
are_VBP an_DT exchange_NN of_IN assets_NNS with_IN no_DT value_NN being_VBG attributed_VBN to_TO Coreg_NNP commonplace_NN ._.
IFRS_NNS ,_, however_RB ,_, requires_VBZ the_DT acquired_VBN rights_NNS to_TO Coreg_NNP to_TO be_VB added_VBN to_TO intangible_JJ assets_NNS at_IN their_PRP$ fair_JJ value_NN on_IN GlaxoSmithKline_NNP believes_VBZ that_IN this_DT reects_VBZ best_JJS practice_NN in_IN revenue_NN the_DT date_NN of_IN acquisition_NN of_IN $_$ 400_CD million_CD ,_, and_CC then_RB amortised_VBN over_IN recognition_NN and_CC hence_RB ,_, in_IN the_DT absence_NN of_IN detailed_JJ guidance_NN under_IN their_PRP$ remaining_VBG useful_JJ life_NN of_IN eight_CD years_NNS ._.
This_DT adjustment_NN reduces_VBZ IFRS_NNP ,_, has_VBZ decided_VBN to_TO adopt_VB a_DT revenue_NN recognition_NN policy_NN under_IN 2004_CD profit_NN before_IN tax_NN by_IN 27_CD million_CD 2003_CD 31_CD million_CD and_CC IFRS_NNP in_IN line_NN with_IN EITF_NNP 01-09_CD ._.
Therefore_RB going_VBG forward_RB there_EX would_MD EPS_VB by_IN 0.3_CD pence_NN 2003_CD 0.3_CD pence_NN ._.
be_VB no_DT difference_NN between_IN turnover_NN reported_VBN under_IN IFRS_NNP and_CC turnover_NN reported_VBN under_IN US_NNP GAAP_NNP ._.
This_DT adjustment_NN has_VBZ no_DT impact_NN Other_JJ intangible_JJ assets_NNS amortisation_NN on_IN profit_NN before_IN tax_NN or_CC EPS_NNP ._.
Under_IN UK_NNP GAAP_NNP ,_, GlaxoSmithKline_NNP amortises_VBZ intangible_JJ assets_NNS over_IN their_PRP$ estimated_VBN expected_VBN useful_JJ lives_NNS from_IN acquisition_NN ,_, which_WDT can_MD Share-based_JJ payments_NNS be_VB up_RB to_TO a_DT maximum_NN of_IN 15_CD years_NNS ._.
IFRS_NNS only_RB permits_VBZ amortisation_NN to_TO The_DT present_JJ UK_NNP GAAP_NNP approach_NN to_TO share-based_JJ payments_NNS is_VBZ to_TO commence_VB when_WRB the_DT asset_NN becomes_VBZ available_JJ for_IN use_NN ,_, with_IN annual_JJ record_NN any_DT intrinsic_JJ loss_NN on_IN grant_NN suffered_VBN by_IN the_DT company_NN ._.
This_DT impairment_NN testing_NN required_VBN before_IN this_DT point_NN ._.
GlaxoSmithKline_NNP has_VBZ means_VBZ that_IN for_IN share_NN options_NNS granted_VBN at_IN the_DT market_NN price_NN ,_, there_EX determined_VBD that_IN the_DT point_NN at_IN which_WDT amortisation_NN of_IN product-related_JJ is_VBZ no_DT charge_NN to_TO the_DT income_NN statement_NN ._.
Where_WRB shares_NNS or_CC options_NNS assets_NNS commences_NNS under_IN IFRS_NNP will_MD normally_RB be_VB regulatory_JJ approval_NN ._.
are_VBP granted_VBN at_IN no_DT cost_NN to_TO the_DT employee_NN e._FW g._FW under_IN long-term_JJ The_DT majority_NN of_IN GlaxoSmithKlines_NNP intangible_JJ assets_NNS relates_VBZ to_TO the_DT incentive_NN plans_VBZ the_DT income_NN statement_NN is_VBZ charged_VBN with_IN an_DT amount_NN acquisition_NN of_IN rights_NNS to_TO compounds_NNS in_IN development_NN and_CC so_RB has_VBZ not_RB equal_JJ to_TO the_DT market_NN price_NN on_IN the_DT date_NN of_IN the_DT award_NN ,_, spread_VBN over_IN reached_VBN the_DT point_NN at_IN which_WDT amortisation_NN commences_NNS ._.
This_DT has_VBZ led_VBN the_DT performance_NN period_NN usually_RB three_CD years_NNS ._.
to_TO a_DT reduction_NN in_IN the_DT amortisation_NN charge_NN in_IN the_DT periods_NNS presented_VBN ,_, IFRS_NNP 2_CD ,_, Share-based_JJ Payment_NN ,_, and_CC its_PRP$ UK_NNP GAAP_NNP equivalent_JJ FRS_NNP 20_CD ,_, which_WDT is_VBZ likely_JJ to_TO reverse_VB in_IN the_DT future_NN as_IN these_DT compounds_NNS reach_VBP Share-based_JJ Payment_NN ,_, both_DT of_IN which_WDT came_VBD into_IN force_NN in_IN 2005_CD ,_, regulatory_JJ approval_NN and_CC amortisation_NN is_VBZ then_RB charged_VBN over_IN a_DT shorter_JJR require_VBP the_DT fair_JJ value_NN of_IN the_DT equity_NN instruments_NNS issued_VBN to_TO be_VB period_NN ._.
profit_NN before_IN tax_NN in_IN 2004_CD increases_NNS by_IN 43_CD million_CD charged_VBN to_TO the_DT income_NN statement_NN ._.
For_IN share_NN awards_NNS granted_VBN to_TO 2003_CD 43_CD million_CD and_CC EPS_NNP by_IN 0.5_CD pence_NN 2003_CD 0.5_CD pence_NN ._.
senior_JJ executives_NNS ,_, although_IN the_DT calculation_NN is_VBZ different_JJ ,_, the_DT resultant_JJ charge_NN is_VBZ not_RB materially_RB different_JJ from_IN that_DT under_IN UK_NNP GAAP_NNP ._.
Goodwill_NN amortisation_NN The_DT major_JJ difference_NN arises_VBZ in_IN respect_NN of_IN share_NN options_NNS :_: of_IN the_DT UK_NNP GAAP_NNP requires_VBZ goodwill_NN to_TO be_VB amortised_VBN over_IN its_PRP$ estimated_VBN 368_CD million_CD adjustment_NN in_IN 2003_CD ,_, some_DT 350_CD million_CD arises_VBZ from_IN expected_VBN useful_JJ life_NN ,_, which_WDT GlaxoSmithKline_NNP has_VBZ determined_VBN the_DT grant_NN of_IN share_NN options_NNS at_IN market_NN price_NN to_TO approximately_RB to_TO be_VB normally_RB no_RB longer_JJR than_IN 20_CD years_NNS ._.
GlaxoSmithKline_NNP has_VBZ chosen_VBN to_TO recognize_VB all_DT goodwill_NN is_VBZ considered_VBN to_TO have_VB an_DT indefinite_JJ life_NN and_CC so_RB is_VBZ not_RB unvested_JJ options_NNS and_CC awards_NNS retrospectively_RB ._.
amortised_JJ ,_, but_CC is_VBZ subject_JJ to_TO annual_JJ impairment_NN testing_NN ._.
This_DT adjustment_NN therefore_RB reverses_VBZ the_DT goodwill_NN amortisation_NN charged_VBD GlaxoSmithKline_NNP receives_VBZ a_DT tax_NN credit_NN ,_, as_IN appropriate_JJ ,_, which_WDT relates_VBZ under_IN UK_NNP GAAP_NNP ,_, including_VBG that_IN recorded_VBN in_IN the_DT profit_NN on_IN share_NN to_TO share_VB options_NNS and_CC awards_NNS when_WRB exercised_VBN ,_, based_VBN on_IN the_DT gains_NNS of_IN associates_NNS line_NN relating_VBG to_TO the_DT acquisition_NN of_IN the_DT Groups_NNS interest_NN the_DT holders_NNS make_VBP and_CC dependant_VBP on_IN the_DT tax_NN rules_NNS in_IN the_DT country_NN in_IN Quest_NNP Diagnostics_NNPS Inc._NNP ._.
Under_IN the_DT business_NN combinations_NNS in_IN which_WDT the_DT deduction_NN is_VBZ claimed_VBN ._.
The_DT deferred_JJ tax_NN asset_NN exemption_NN of_IN IFRS_NNP 1_CD ,_, goodwill_NN previously_RB written_VBN off_RP direct_JJ to_TO represents_VBZ an_DT estimate_NN of_IN future_JJ tax_NN relief_NN for_IN this_DT gain_NN and_CC is_VBZ reserves_NNS under_IN UK_NNP GAAP_NNP is_VBZ not_RB recycled_VBN to_TO the_DT income_NN statement_NN based_VBN on_IN the_DT potential_JJ gains_NNS available_JJ to_TO the_DT option_NN or_CC award_NN on_IN the_DT disposal_NN or_CC part-disposal_NN of_IN the_DT subsidiary_NN or_CC associate_NN ,_, holders_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT movement_NN in_IN deferred_VBN as_IN it_PRP would_MD be_VB under_IN UK_NNP GAAP_NNP ._.
The_DT adjustment_NN increases_VBZ 2004_CD tax_NN asset_NN from_IN one_CD balance_NN sheet_NN to_TO the_DT next_JJ may_MD result_VB in_IN either_CC a_DT profit_NN before_IN tax_NN by_IN 38_CD million_CD 2003_CD 26_CD million_CD and_CC EPS_NNP by_IN tax_NN credit_NN or_CC a_DT tax_NN charge_NN recorded_VBN in_IN the_DT income_NN statement_NN ._.
This_DT adjustment_NN reduces_VBZ profit_NN before_IN tax_NN in_IN 2004_CD by_IN 309_CD million_CD 2003_CD 368_CD million_CD ,_, earnings_NNS by_IN 314_CD million_CD 2003_CD 344_CD million_CD and_CC EPS_NNP by_IN 5.5_CD pence_NN 2003_CD 5.9_CD pence_NN ._.
168_CD GlaxoSmithKline_NNP Financial_NNP information_NN under_IN IFRS_NNP IFRS_NNP adjustments_NNS continued_VBD Deferred_JJ tax_NN on_IN intercompany_NN profit_NN Under_IN UK_NNP GAAP_NNP ,_, deferred_VBN tax_NN on_IN the_DT provision_NN for_IN intercompany_NN Pensions_NNS and_CC other_JJ post-employment_NN benets_NNS profit_NN held_VBN in_IN inventory_NN is_VBZ calculated_VBN at_IN the_DT supplying_VBG companys_NNS GlaxoSmithKline_NNP accounts_VBZ under_IN UK_NNP GAAP_NNP for_IN pensions_NNS and_CC other_JJ effective_JJ tax_NN rate_NN ._.
IFRS_NNS ,_, however_RB ,_, takes_VBZ a_DT balance_NN sheet_NN approach_NN post-employment_NN benets_NNS OPEBs_NNS in_IN accordance_NN with_IN SSAP_NNP 24_CD ,_, to_TO the_DT recognition_NN of_IN deferred_JJ tax_NN which_WDT results_NNS in_IN the_DT tax_NN rate_NN of_IN which_WDT spreads_VBZ the_DT costs_NNS of_IN providing_VBG the_DT benets_NNS over_IN the_DT the_DT company_NN holding_VBG the_DT inventory_NN at_IN the_DT balance_NN sheet_NN date_NN estimated_VBN average_JJ service_NN lives_NNS of_IN the_DT employees_NNS ._.
The_DT additional_JJ being_VBG applied_VBN to_TO the_DT provision_NN ._.
If_IN the_DT proportions_NNS of_IN the_DT Groups_NNS FRS_NNP 17_CD disclosures_NNS give_VBP the_DT pension_NN fund_NN surpluses_NNS and_CC deficits_NNS inventory_NN held_VBN in_IN specic_JJ locations_NNS change_VBP signicantly_RB from_IN one_CD and_CC the_DT liabilities_NNS for_IN OPEBs_NNS based_VBN on_IN the_DT valuation_NN methodologies_NNS balance_NN sheet_NN date_NN to_TO the_DT next_JJ there_EX could_MD be_VB a_DT significant_JJ change_NN required_VBN by_IN that_DT Standard_NNP ._.
in_IN the_DT value_NN of_IN the_DT deferred_JJ tax_NN asset_NN ,_, which_WDT is_VBZ reected_VBN through_IN IAS_NNP 19_CD ,_, Employee_NNP Benets_NNPS ,_, takes_VBZ a_DT similar_JJ valuation_NN approach_NN to_TO the_DT tax_NN charge_NN for_IN the_DT year_NN ._.
FRS_NNP 17_CD ,_, and_CC in_IN accordance_NN with_IN the_DT transitional_JJ provisions_NNS of_IN IFRS_NNP 1_CD the_DT surpluses_NNS and_CC deficits_NNS have_VBP been_VBN recognized_VBN on_IN the_DT balance_NN Other_JJ adjustments_NNS sheet_NN at_IN the_DT transition_NN date_NN of_IN 1st_CD January_NNP 2003_CD ._.
In_IN addition_NN ,_, There_EX are_VBP a_DT number_NN of_IN other_JJ minor_JJ adjustments_NNS and_CC following_VBG an_DT amendment_NN to_TO IAS_NNP 19_CD issued_VBN by_IN the_DT IASB_NNP in_IN December_NNP reclassications_NNS ,_, including_VBG :_: 2004_CD ,_, it_PRP is_VBZ permitted_VBN to_TO recognize_VB any_DT movements_NNS in_IN the_DT surpluses_NNS Computer_NN software_NN ,_, which_WDT is_VBZ recorded_VBN as_IN an_DT intangible_JJ asset_NN or_CC deficits_NNS immediately_RB in_IN balance_NN sheets_NNS ,_, but_CC outside_IN the_DT income_NN unless_IN it_PRP forms_VBZ an_DT integral_JJ part_NN of_IN the_DT operating_NN system_NN of_IN a_DT statement_NN ,_, in_IN a_DT similar_JJ way_NN to_TO FRS_NNP 17_CD ._.
This_DT means_VBZ that_IN ,_, in_IN most_JJS tangible_JJ xed_JJ asset_NN cases_NNS ,_, the_DT balance_NN sheet_NN reects_VBZ the_DT full_JJ surplus_NN or_CC deficit_NN positions_NNS Deferred_VBN tax_NN on_IN brands_NNS acquired_VBN with_IN a_DT company_NN ,_, where_WRB if_IN of_IN the_DT funds_NNS ._.
there_EX is_VBZ a_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT brands_NNS on_IN The_DT Groups_NNS policy_NN is_VBZ to_TO charge_VB out_RP to_TO the_DT operating_NN businesses_NNS acquisition_NN and_CC the_DT tax_NN value_NN ,_, a_DT taxable_JJ temporary_JJ difference_NN the_DT service_NN cost_NN element_NN of_IN the_DT pension_NN charge_NN ,_, which_WDT then_RB gets_VBZ arises_VBZ reported_VBN within_IN cost_NN of_IN sales_NNS ,_, selling_NN ,_, general_JJ and_CC administrative_JJ Cash_NN equivalents_NNS reclassication_NN ,_, where_WRB liquid_JJ investments_NNS expenditure_NN or_CC research_NN and_CC development_NN as_IN appropriate_JJ ,_, but_CC not_RB with_IN maturities_NNS of_IN less_JJR than_IN three_CD months_NNS at_IN acquisition_NN are_VBP to_TO charge_VB out_RP the_DT element_NN related_VBN to_TO the_DT funding_NN deficit_NN ,_, which_WDT included_VBD within_IN cash_NN and_CC cash_NN equivalents_NNS ,_, and_CC is_VBZ all_DT reported_VBN in_IN Selling_NNP ,_, general_JJ and_CC administrative_JJ expenditure_NN ._.
Provisions_NNS reclassication_NN ,_, where_WRB the_DT elements_NNS of_IN provisions_NNS Under_IN IAS_NNP 19_CD ,_, the_DT service_NN cost_NN element_NN of_IN the_DT total_JJ charge_NN is_VBZ expected_VBN to_TO be_VB paid_VBN within_IN one_CD year_NN of_IN the_DT balance_NN sheet_NN date_NN ,_, considerably_RB higher_JJR than_IN under_IN SSAP_NNP 24_CD and_CC the_DT funding_NN deficit_NN with_IN the_DT exception_NN of_IN pensions_NNS and_CC OPEBs_NNS ,_, are_VBP presented_VBN element_NN lower_JJR ._.
This_DT leads_VBZ to_TO an_DT additional_JJ reclassication_NN within_IN current_JJ liabilities_NNS ._.
adjustment_NN between_IN the_DT income_NN statement_NN expense_NN headings_NNS ._.
Cash_NN ow_NN statement_NN In_IN the_DT USA_NNP ,_, the_DT recently_RB enacted_VBN Medicare_NNP Prescription_NNP Drug_NNP ,_, The_DT move_NN from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP does_VBZ not_RB change_VB any_DT of_IN the_DT cash_NN Improvement_NNP and_CC Modernization_NNP Act_NNP is_VBZ expected_VBN to_TO lead_VB to_TO ows_NNS of_IN the_DT Group_NNP ._.
The_DT IFRS_NNP cash_NN ow_NN format_NN is_VBZ similar_JJ to_TO UK_NNP payments_NNS being_VBG received_VBN by_IN GlaxoSmithKline_NNP from_IN the_DT US_NNP GAAP_NNP but_CC presents_VBZ various_JJ cash_NN ows_NNS in_IN different_JJ categories_NNS and_CC Government_NN in_IN respect_NN of_IN its_PRP$ employee_NN healthcare_NN plans_NNS ._.
At_IN in_IN a_DT different_JJ order_NN from_IN the_DT UK_NNP GAAP_NNP cash_NN ow_NN statement_NN ._.
All_DT present_JJ there_EX is_VBZ no_DT clear_JJ consensus_NN on_IN how_WRB these_DT receipts_NNS should_MD of_IN the_DT IFRS_NNP accounting_NN adjustments_NNS net_JJ out_IN within_IN cash_NN generated_VBD be_VB accounted_VBN for_IN under_IN IAS_NNP 19_CD ._.
GlaxoSmithKline_NNP has_VBZ recognized_VBN from_IN operations_NNS except_IN for_IN the_DT intangible_JJ assets_NNS reclassication_NN these_DT receipts_NNS as_IN actuarial_JJ adjustments_NNS and_CC so_IN the_DT impact_NN of_IN them_PRP and_CC the_DT inclusion_NN of_IN liquid_JJ investments_NNS with_IN a_DT maturity_NN of_IN less_JJR is_VBZ recognized_VBN in_IN the_DT balance_NN sheet_NN ._.
This_DT treatment_NN would_MD change_VB if_IN than_IN three_CD months_NNS on_IN acquisition_NN ,_, together_RB with_IN related_JJ exchange_NN guidance_NN is_VBZ issued_VBN which_WDT requires_VBZ a_DT different_JJ accounting_NN treatment_NN ._.
adjustments_NNS ,_, within_IN cash_NN and_CC cash_NN equivalents_NNS under_IN IFRS_NNP ._.
The_DT overall_JJ impact_NN of_IN the_DT adjustments_NNS to_TO pensions_NNS and_CC OPEBs_NNS in_IN 2004_CD is_VBZ a_DT decrease_NN in_IN profit_NN before_IN tax_NN of_IN 36_CD million_CD 2003_CD increase_NN of_IN 11_CD million_CD and_CC a_DT decrease_NN in_IN EPS_NNP of_IN 0.4_CD pence_NN 2003_CD nil_NN ._.
Share_NN of_IN profits_NNS of_IN associates_NNS Under_IN UK_NNP GAAP_NNP the_DT share_NN of_IN profits_NNS of_IN associates_NNS is_VBZ reported_VBN within_IN profit_NN before_IN tax_NN for_IN the_DT Group_NNP ._.
However_RB ,_, IFRS_NNP requires_VBZ this_DT share_NN of_IN profits_NNS to_TO be_VB the_DT net_JJ profit_NN attributable_JJ to_TO the_DT Group_NNP ,_, i._FW e._FW after_IN interest_NN ,_, tax_NN and_CC minority_NN interests_NNS of_IN the_DT associate_NN ._.
This_DT leads_VBZ to_TO a_DT reclassication_NN adjustment_NN removing_VBG the_DT share_NN of_IN the_DT associates_NNS interest_NN ,_, tax_NN and_CC minority_NN interests_NNS from_IN those_DT lines_NNS in_IN the_DT income_NN statement_NN and_CC netting_VBG them_PRP all_DT together_RB in_IN the_DT share_NN of_IN profits_NNS of_IN associates_NNS line_NN ._.
This_DT adjustment_NN reduces_VBZ 2004_CD profit_NN before_IN tax_NN by_IN 42_CD million_CD 2003_CD 42_CD million_CD but_CC does_VBZ not_RB affect_VB EPS_NNP ._.
